John Lubniewski - HTG Molecular Chief Bus. Officer
| HTGMDelisted Stock | USD 0.57 0.20 54.05% |
Executive
Mr. John L. Lubniewski is President, Chief Executive Officer, Director of the Company. Mr. Lubniewski joined us from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of Roche Tissue Diagnostics where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche in March 2008. From August 2010 to April 2011, Mr. Lubniewski was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010, Mr. Lubniewski served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit, and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years at Corning, Inc., a manufacturing company, in a variety of divisional, sector and corporate sales and marketing roles since 2019.
| Age | 59 |
| Tenure | 5 years |
| Phone | 877 289 2615 |
| Web | https://www.htgmolecular.com |
HTG Molecular Management Efficiency
The company has return on total asset (ROA) of (0.6226) % which means that it has lost $0.6226 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4321) %, meaning that it created substantial loss on money invested by shareholders. HTG Molecular's management efficiency ratios could be used to measure how well HTG Molecular manages its routine affairs as well as how well it operates its assets and liabilities.HTG Molecular Diagnostics currently holds 4.83 M in liabilities with Debt to Equity (D/E) ratio of 2.52, implying the company greatly relies on financing operations through barrowing. HTG Molecular Diagnostics has a current ratio of 1.86, which is within standard range for the sector. Note, when we think about HTG Molecular's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 11 records | EXECUTIVE Age | ||
| Shannon Shoemaker | Psychemedics | 38 | |
| CPA BCom | Genetic Technologies | 57 | |
| Victoria Gavrilenko | Intelligent Bio Solutions | 41 | |
| William Bauta | bioAffinity Technologies Warran | N/A | |
| Michael Weisenhoff | Psychemedics | 34 | |
| Dallas Coleman | bioAffinity Technologies Warran | N/A | |
| Dallas Coleman | bioAffinity Technologies, | N/A | |
| Patrick Kinney | Psychemedics | N/A | |
| Daniella Mehalik | Psychemedics | 34 | |
| Roger Smith | T2 Biosystms | 59 | |
| William Bauta | bioAffinity Technologies, | N/A | |
Management Performance
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 |
HTG Molecular Diagnostics Leadership Team
Elected by the shareholders, the HTG Molecular's board of directors comprises two types of representatives: HTG Molecular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HTG. The board's role is to monitor HTG Molecular's management team and ensure that shareholders' interests are well served. HTG Molecular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HTG Molecular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Laura Godlewski, Principal Accounting Officer | ||
| Shaun McMeans, CFO and VP of Fin. and Admin. | ||
| John Lubniewski, Chief Bus. Officer | ||
| Stephen Barat, VP Therapeutics | ||
| Byron Lawson, VP Officer | ||
| Debra Gordon, Vice President and Chief Legal Counsel | ||
| Patrick Roche, Senior Vice President - Research and Product Development |
HTG Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HTG Molecular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (3.15) % | |||
| Current Valuation | 2.56 M | |||
| Shares Outstanding | 2.21 M | |||
| Shares Owned By Insiders | 6.54 % | |||
| Shares Owned By Institutions | 0.74 % | |||
| Number Of Shares Shorted | 2.73 K | |||
| Price To Earning | (0.88) X | |||
| Price To Book | 6.26 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in HTG Stock
If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |